Chemo-Pharma [CPL] vs Uniparts India [UNIPARTS] Detailed Comparison
Chemo-Pharma
BSE
Loading...
Uniparts India
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemo-Pharma wins in 9 metrics, Uniparts India wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Uniparts India | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.21 | 19.48 | Chemo-Pharma |
| Price-to-Book Ratio | 2.96 | 1.93 | Uniparts India |
| Debt-to-Equity Ratio | 44.70 | 13.52 | Uniparts India |
| PEG Ratio | N/A | -0.64 | N/A |
| EV/EBITDA | 15.63 | 10.69 | Uniparts India |
| Profit Margin (TTM) | 10.92% | 9.13% | Chemo-Pharma |
| Operating Margin (TTM) | 10.65% | 9.62% | Chemo-Pharma |
| EBITDA Margin (TTM) | 10.65% | 9.62% | Chemo-Pharma |
| Return on Equity | 25.59% | 10.03% | Chemo-Pharma |
| Return on Assets (TTM) | 6.80% | 5.51% | Chemo-Pharma |
| Free Cash Flow (TTM) | $41.66M | $1.49B | Uniparts India |
| Dividend Yield | N/A | 3.81% | N/A |
| 1-Year Return | 38.64% | -24.24% | Chemo-Pharma |
| Price-to-Sales Ratio (TTM) | 1.65 | 1.90 | Chemo-Pharma |
| Enterprise Value | $5.03B | $15.56B | Uniparts India |
| EV/Revenue Ratio | 1.75 | 1.61 | Uniparts India |
| Gross Profit Margin (TTM) | 31.19% | 61.85% | Uniparts India |
| Revenue per Share (TTM) | $52 | $214 | Uniparts India |
| Earnings per Share (Diluted) | $6.02 | $19.48 | Uniparts India |
| Beta (Stock Volatility) | 0.35 | 0.69 | Chemo-Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Uniparts India Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -2.35% | 1.69% | 4.48% | -15.16% | -28.20% | -35.30% |
| Uniparts India | -2.32% | -3.67% | -4.19% | 12.82% | 2.85% | -10.31% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | 38.64% | 393.51% | 115.30% | 982.62% | 1,384.38% | 1,384.38% |
| Uniparts India | -24.24% | 201.01% | 210.92% | 130.66% | 130.66% | 130.66% |
Performance & Financial Health Analysis: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.75B | ₹18.29B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 34,895 | 37,535 |
| 90 Day Avg. Volume | 36,751 | 50,117 |
| Last Close | ₹75.25 | ₹370.40 |
| 52 Week Range | ₹52.25 - ₹128.00 | ₹296.65 - ₹521.95 |
| % from 52W High | -41.21% | -29.04% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹722.65 (Jul 31, 2023) |
| % from All-Time High | -41.21% | -48.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | -0.13% |
| Quarterly Earnings Growth | -0.04% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.09% |
| Operating Margin (TTM) | 0.11% | 0.10% |
| Return on Equity (TTM) | 0.26% | 0.10% |
| Debt to Equity (MRQ) | 44.70 | 13.52 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹196.66 |
| Cash per Share (MRQ) | ₹1.07 | ₹61.22 |
| Operating Cash Flow (TTM) | ₹89.49M | ₹1.82B |
| Levered Free Cash Flow (TTM) | ₹-72,916,248 | ₹1.32B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.81% |
| Last 12-Month Dividend | ₹0.00 | ₹14.25 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.21 | 19.48 |
| Forward P/E | N/A | 13.74 |
| PEG Ratio | N/A | -0.64 |
| Price to Sales (TTM) | 1.65 | 1.90 |
| Price to Book (MRQ) | 2.96 | 1.93 |
| Market Capitalization | ||
| Market Capitalization | ₹4.75B | ₹18.29B |
| Enterprise Value | ₹5.03B | ₹15.56B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.75 | 1.61 |
| Enterprise to EBITDA | 15.63 | 10.69 |
| Risk & Other Metrics | ||
| Beta | 0.35 | 0.69 |
| Book Value per Share (MRQ) | ₹26.86 | ₹196.66 |
Financial Statements Comparison: Chemo-Pharma vs Uniparts India
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Revenue/Sales | ₹784.51M | ₹2.53B |
| Cost of Goods Sold | ₹539.82M | ₹964.47M |
| Gross Profit | ₹244.69M | ₹1.56B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹83.57M | ₹243.19M |
| EBITDA | ₹98.07M | ₹416.41M |
| Pre-Tax Income | ₹68.08M | ₹287.68M |
| Income Tax | ₹16.93M | ₹59.40M |
| Net Income (Profit) | ₹51.16M | ₹228.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹328.89M |
| Total Current Assets | ₹2.51B | ₹8.14B |
| Total Current Liabilities | ₹1.17B | ₹2.16B |
| Long-Term Debt | ₹109.50M | ₹263.82M |
| Total Shareholders Equity | ₹1.49B | ₹8.87B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.04M | ₹2.57B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | UNIPARTS |
|---|---|---|
| Operating Cash Flow | N/A | ₹492.10M |
| Capital Expenditures | N/A | ₹-68.61M |
| Free Cash Flow | N/A | ₹92.68M |
| Debt Repayment | N/A | ₹-4.03M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | UNIPARTS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 34,895 | 37,535 |
| Average Daily Volume (90 Day) | 36,751 | 50,117 |
| Shares Outstanding | 57.55M | 44.98M |
| Float Shares | 15.95M | 15.07M |
| % Held by Insiders | 0.70% | 0.66% |
| % Held by Institutions | 0.00% | 0.05% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Uniparts India
| Metric | CPL | UNIPARTS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹14.25 |
| Last 12-Month Dividend Yield | N/A | 3.81% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹14.17 |
| 3-Year Avg Dividend Yield | N/A | 1.47% |
| 3-Year Total Dividends | ₹0.00 | ₹42.50 |
| Ex-Dividend Date | N/A | Feb 12, 2025 |